Quotient Ltd.

Quotient Ltd.

Quotient Ltd.

Overview
Date Founded

2012

Headquarters

B1, Business Park Terre Bonne, Route de Crassier 13, Eysins, 1262, CHE

Type of Company

Public

Employees (Worldwide)

410

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals

Company Description

Quotient Ltd. is a commercial-stage diagnostics company. It provides immunohematology products to hospitals and blood banks. The company develops, manufactures and sells conventional reagent products to equipment manufacturers. It engages in transfusion diagnostics, which focuses on blood grouping and serological disease screening. Quotient was founded on January 28, 2012 and is headquartered in Eysins, Switzerland.

Contact Data
Trying to get in touch with decision makers at Quotient Ltd.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Co-President

Chief Financial Officer

Group Controller & Treasurer

Professional

Professional

Professional

Professional

Professional

Board of Directors

Chairman at Quotient Biodiagnostics, Inc.

Former Chief Legal Officer & Senior Vice President-Strategic Development at Arch Chemicals, Inc.

Founder at Hallsworth Ltd

Chief Executive Officer at Quotient Ltd.

Founder at Galen Partners LLC

Managing Partner at Galen Collaborative Capital

Investment Partner at Galen Collaborative Capital

Professional at Quotient Ltd.

Member, Board of Directors at Quotient Ltd.

Paths to Quotient Ltd.
Potential Connections via
Relationship Science
You
Quotient Ltd.
Owners & Shareholders
Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund's investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in \"crossover\" (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant's or their affiliates' proprietary capital.

Details Hidden

RTW Investments employs an event-driven investment strategy that focuses on long/short investments in US healthcare companies. The firm invests primarily in the stocks of: (1) pharmaceutical companies (2) medical device manufacturers and (3) diagnostic tool manufacturers. RTW Investments also makes select investments in derivatives and fixed-income instruments.

Recent Transactions
Details Hidden

Quotient Ltd. raised money in a private placement transaction

Details Hidden

Quotient Ltd. issued USD Ordinary Shares

Details Hidden

Quotient Ltd. issued USD Ordinary Shares

Transaction Advisors
Escrow Agent

Advised onQuotient Ltd. issued USD Ordinary Shares

Auditor

Advised onQuotient Ltd. issued Ordinary Shares

Underwriter

Advised onQuotient Ltd. issued USD Ordinary Shares

Global Joint Head of Pharmaceuticals & Life

Advised onQuotient Ltd. issued USD Ordinary Shares

Underwriter

Advised onQuotient Ltd. issued Ordinary Shares

Advisors & Consultants
Advisor

Chief Executive Officer at Quotient Bioscience Ltd.

Clients

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the following segments: Life Sciences and Clinical Diagnostics. The Life Science segment develops, manufactures and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialize in quality controls that serve clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Ortho-Clinical Diagnostics, Inc. manufactures, designs diagnostic, transfusion, clinical equipment and systems. It provides total solutions for screening, diagnosing, monitoring and confirming diseases early before they put lives at risk. The firm products include instrument systems and reagents that screen for AIDS and hepatitis C, as well as blood typing systems. The company was founded in 1997 and is headquartered in Raritan, NJ.

Key Stats and Financials As of 2019
Market Capitalization
$487M
Total Enterprise Value
$542M
Earnings Per Share
$-1.92
Revenue
$29.1M
Net Profit
$-105M
EBITDA
$-66.5M
EBITDAMargin
-228.38%
Total Debt
$143M
Total Equity
$1.71M
Enterprise Value Sales
18.61x
TEVNet Income
-5.14x
Debt TEV
0.26x
Three Year Compounded Annual Growth Rate Of Revenue
16.3%
Five Year Compounded Annual Growth Rate Of Revenue
8.08%
Investors
Details Hidden

Investor Director at Grapeshot Ltd.

Details Hidden

Galen Collaborative Capital focuses exclusively on investments in the healthcare sector including healthcare technology-enabled services, healthcare information technology, medical devices and specialty pharmaceutical companies. The firm seeks to make mid- to late-stage investments in healthcare companies that have achieved scale in traditional and emerging growth segments. Galen looks to invest in proprietary products or services that have attained a revenue run-rate greater than $10 million and that have near-term prospects for positive cash flow. Galen typically invests in convertible preferred equity securities with an initial placement of at least $10 million. Investments typically range from $10 million to $30 million, but Galen will invest in syndicate in transactions up to $100 million. The firm's growth-oriented portfolio offers limited partners direct investment opportunities in privately placed equity, mezzanine debt and senior debt

Suppliers
TTP Communications Plc Wireless Telecommunications | Royston, HD

TTP communications Plc provides wireless communications services. It engages in the development and commercial licensing of technology and intellectual property which are used in the designing and manufacturing of wireless communications terminals, such as mobile telephones, personal digital assistants, and wireless modules. TTP communications was founded in 1988 and is located in Melbourn Royston, UK.

Merck KGaA Hospitals & Patient Services | Darmstadt, HE

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and Performance Materials. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Stratec SE Industrial Machinery & Manufacturing | Birkenfeld, RP

STRATEC SE engages in the design and manufacture of automated analyzer systems in the fields of clinical diagnostic and biotechnology. It operates through the following segments: Instrumentation, Diatron, Smart Consumables, and Other Activities. The Instrumentation segment consults, designs, develops and produces fully automated solutions for its partners in the fields of diagnostics including blood banking. The Diatron segment comprises the business with systems, system components, consumables and tests in the low throughput hematology and clinical chemistry segment. The Smart Consumables segment includes the business with developing and manufacturing smart consumables in the fields of diagnostics, life sciences, and medical technology. The Other Activities segment covers the development of work flow software for networking several analyzer systems and the development and sale of scientific materials and technologies. The company was founded by Hermann Leistner in 1979 and is headquartered in Birkenfeld, Germany.

Competitors
Danaher Corporation Industrial Machinery & Manufacturing - Washington, DC

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following five segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products and services that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as to improve the aesthetics of the human smile. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Roche Holding AG Pharmaceuticals - Basel, BS

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Quotient Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Quotient Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Quotient Ltd..